Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Abington Neurological Associates
mi
from
Willow Grove, PA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Abington Neurological Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Simpson's Pharmacy
mi
from
Pawtucket, RI
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Simpson's Pharmacy
mi
from
Pawtucket, RI
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Butler Hospital
mi
from
Providence, RI
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Medical University of South Carolina Hospitals and Clinics
mi
from
Charleston, SC
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Medical University of South Carolina Hospitals and Clinics
mi
from
Charleston, SC
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Medical University of South Carolina Investigational Drug Service
mi
from
Charleston, SC
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Medical University of South Carolina Investigational Drug Service
mi
from
Charleston, SC
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Radiant Research, Incorporated
mi
from
Greer, SC
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Radiant Research, Incorporated
mi
from
Greer, SC
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Medical University of South Carolina
mi
from
North Charleston, SC
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Medical University of South Carolina
mi
from
North Charleston, SC
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Neurology Clinic, PC
mi
from
Cordova, TN
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Neurology Clinic, PC
mi
from
Cordova, TN
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Austin Infusion Centers
mi
from
Austin, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Austin Infusion Centers
mi
from
Austin, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Senior Adults Specialty Research
mi
from
Austin, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Senior Adults Specialty Research
mi
from
Austin, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Texas Neurology, PA
mi
from
Dallas, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Innovative Clinical Trials
mi
from
San Antonio, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Innovative Clinical Trials
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Integra Clinical Research
mi
from
San Antonio, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Integra Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Vista Infusions
mi
from
San Antonio, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Vista Infusions
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Inventive Infusion Solutions
mi
from
San Antonio, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Inventive Infusion Solutions
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Southwestern Vermont Healthcare
mi
from
Bennington, VT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Southwestern Vermont Healthcare
mi
from
Bennington, VT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
The Memory Clinic
mi
from
Bennington, VT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
University of Virginia Neurology
mi
from
Charlottesville, VA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
University of Virginia Neurology
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
University Of Virginia General Clinical Research Center
mi
from
Charlottesville, VA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
University Of Virginia General Clinical Research Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
University of Viriginia Investigational Pharmacy
mi
from
Charlottesville, VA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
University of Viriginia Investigational Pharmacy
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Pacific Medical Centers
mi
from
Bothell, WA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Pacific Medical Centers
mi
from
Bothell, WA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Pacific Medical Centers
mi
from
Seattle, WA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Pacific Medical Centers
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Cemic University Hospital
mi
from
Buenos Aires,
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Cemic University Hospital
mi
from
Buenos Aires,
Click here to add this to my saved trials
Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD
Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD
Status: Enrolling
Updated:  12/18/2015
The Mayo Clinic
mi
from
Rochester, MN
Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD
Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD
Status: Enrolling
Updated: 12/18/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated:  1/4/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated: 1/4/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated:  1/4/2016
Stanford University and Veterans Affairs
mi
from
Menlo Park, CA
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated: 1/4/2016
Stanford University and Veterans Affairs
mi
from
Menlo Park, CA
Click here to add this to my saved trials
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated:  1/4/2016
University of Miami at Miami, Center on Adult Development and Aging
mi
from
Miami, FL
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated: 1/4/2016
University of Miami at Miami, Center on Adult Development and Aging
mi
from
Miami, FL
Click here to add this to my saved trials
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated:  1/4/2016
Thomas Jefferson University at Philadelphia, Center for Applied Research on Aging and Health
mi
from
Philadelphia, PA
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated: 1/4/2016
Thomas Jefferson University at Philadelphia, Center for Applied Research on Aging and Health
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated:  1/4/2016
University of Tennessee Health Science Center
mi
from
Memphis, TN
Coordinating Center for Caregiver Intervention Trial
Coordinating Center for Multisite Intervention Trial for Diverse Caregivers
Status: Enrolling
Updated: 1/4/2016
University of Tennessee Health Science Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's
A Study to Examine the Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's Disease
Status: Enrolling
Updated:  1/11/2016
Botsford Continuing Care
mi
from
Farmington Hills, MI
Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's
A Study to Examine the Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's Disease
Status: Enrolling
Updated: 1/11/2016
Botsford Continuing Care
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads
Project BEST-Sleep: A Pilot Study to Develop a Biobehavioral Self-Management Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads
Status: Enrolling
Updated:  1/11/2016
Jewish Senior Services
mi
from
Fairfield, CT
Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads
Project BEST-Sleep: A Pilot Study to Develop a Biobehavioral Self-Management Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads
Status: Enrolling
Updated: 1/11/2016
Jewish Senior Services
mi
from
Fairfield, CT
Click here to add this to my saved trials
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)
A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers
Status: Enrolling
Updated:  1/12/2016
WCCT
mi
from
Cypress, CA
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)
A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers
Status: Enrolling
Updated: 1/12/2016
WCCT
mi
from
Cypress, CA
Click here to add this to my saved trials
A Composite MR Neuroimaging Marker for Alzheimer's Disease
A Composite MR Neuroimaging Marker for Alzheimer's Disease
Status: Enrolling
Updated:  1/13/2016
Medical College of Wisconsin/ Froedtert Hospital
mi
from
Milwaukee, WI
A Composite MR Neuroimaging Marker for Alzheimer's Disease
A Composite MR Neuroimaging Marker for Alzheimer's Disease
Status: Enrolling
Updated: 1/13/2016
Medical College of Wisconsin/ Froedtert Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Dose Response Study of Aerobic Exercise in Older Adults
Dose Response Study of Exercise for Age-related Cognitive Changes
Status: Enrolling
Updated:  1/14/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Dose Response Study of Aerobic Exercise in Older Adults
Dose Response Study of Exercise for Age-related Cognitive Changes
Status: Enrolling
Updated: 1/14/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Status: Enrolling
Updated:  1/18/2016
Lifespan
mi
from
Providence, RI
Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Status: Enrolling
Updated: 1/18/2016
Lifespan
mi
from
Providence, RI
Click here to add this to my saved trials
Augmenting 18F-AV-1451 Dosimetry Estimates
A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451
Status: Enrolling
Updated:  1/21/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Augmenting 18F-AV-1451 Dosimetry Estimates
A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451
Status: Enrolling
Updated: 1/21/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  1/27/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 1/27/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Banner Boswell Medical Center
mi
from
Sun City, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Banner Boswell Medical Center
mi
from
Sun City, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Banner Lakes Imaging Center
mi
from
Sun City, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Banner Lakes Imaging Center
mi
from
Sun City, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Southwest PET Institute
mi
from
Tucson, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Southwest PET Institute
mi
from
Tucson, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
University of Arizona, Health Sciences Center - Department of Neurology
mi
from
Tucson, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
University of Arizona, Health Sciences Center - Department of Neurology
mi
from
Tucson, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Universal Medical Center
mi
from
Tucson, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Universal Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated:  1/28/2016
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.
Status: Enrolling
Updated: 1/28/2016
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
Click here to add this to my saved trials